Buy Generic Seroflo Inhaler Online

Generic Seroflo Inhaler Information

Introduction

Seroflo Inhaler is a fixed‑dose combination inhalation product containing the corticosteroid fluticasone propionate and the long‑acting β2‑agonist (LABA) salmeterol xinafoate. It is indicated for the long‑term, daily maintenance treatment of asthma in adults and for the prevention of symptoms in chronic obstructive pulmonary disease (COPD) where approved. In Hong Kong, where the prevalence of adult asthma is estimated at 5–7 % (Hong Kong Centre for Health Protection, 2023), effective maintenance therapy is essential to reduce exacerbations, improve lung function, and maintain quality of life. The inhaler is supplied by a licensed manufacturer that meets the standards of the Hong Kong Department of Health and international regulatory agencies.

What is Seroflo Inhaler?

Seroflo Inhaler is a metered‑dose inhaler (MDI) that delivers a fixed combination of fluticasone propionate (a potent inhaled corticosteroid) and salmeterol xinafoate (a long‑acting β2‑adrenergic agonist). The product belongs to the class of combination inhaled corticosteroid/long‑acting β2‑agonist (ICS/LABA) therapies, which are recommended by the Global Initiative for Asthma (GINA) as preferred controller options for patients whose asthma is not adequately controlled with low‑dose inhaled corticosteroids alone. The device uses hydrofluoroalkane (HFA) propellant technology, providing consistent dose delivery without the need for a breath‑actuated mechanism.

Manufacturing of Seroflo Inhaler complies with Good Manufacturing Practice (GMP) standards; the specific company overseeing production is a registered pharmaceutical firm authorized to export inhalation products to Hong Kong and other Asian markets.

How Seroflo Inhaler Works

Fluticasone propionate exerts anti‑inflammatory effects by binding to glucocorticoid receptors in airway epithelial cells and immune cells, reducing the transcription of pro‑inflammatory cytokines, chemokines, and adhesion molecules. This diminishes airway edema, mucus production, and hyper‑responsiveness.

Salmeterol xinafoate is a selective agonist of the β2‑adrenergic receptor on airway smooth muscle. Activation of this receptor increases intracellular cyclic AMP, leading to relaxation of bronchial smooth muscle and sustained bronchodilation for up to 12 hours.

When combined, the corticosteroid addresses the underlying inflammation, while the LABA provides persistent bronchodilation, allowing better symptom control, fewer nocturnal awakenings, and reduced need for rescue short‑acting β2‑agonists. Onset of bronchodilation occurs within 15 minutes, with peak anti‑inflammatory activity achieved after repeated daily dosing. Systemic absorption is minimal; the majority of the dose is deposited in the lungs and cleared via hepatic metabolism (fluticasone via CYP3A4, salmeterol via CYP3A4 and CYP2D6).

Conditions Treated with Seroflo Inhaler

• Persistent Asthma (Step 3–5 therapy) – Recommended for adults whose asthma remains uncontrolled on low‑dose inhaled corticosteroids. Clinical trials have shown a 30‑40 % reduction in severe exacerbations compared with corticosteroid monotherapy.
• COPD (Maintenance therapy) – In regions where regulatory approval is granted, the combination helps reduce COPD exacerbations and improves FEV₁ (forced expiratory volume in one second).
• Exercise‑Induced Bronchoconstriction (adjunct) – While not a primary indication, the anti‑inflammatory component may lessen airway hyper‑responsiveness triggered by physical activity.

In Hong Kong, the high humidity and seasonal air pollutants elevate the risk of asthma exacerbations; a maintenance regimen with an ICS/LABA such as Seroflo Inhaler aligns with local clinical guidelines for optimal disease control.

Who is Seroflo Inhaler For?

• Adults (≥ 18 years) with moderate to severe persistent asthma who require step‑up therapy beyond low‑dose inhaled corticosteroids.
• Patients with a history of frequent rescue inhaler use (≥ 2 times per week) or night‑time symptoms.
• Individuals who prefer a single inhaler device that combines anti‑inflammatory and bronchodilator actions, simplifying adherence.
• COPD patients (where approved) who experience dyspnoea despite long‑acting bronchodilator monotherapy.

Contraindications / Cautions – Seroflo Inhaler should be avoided in patients with known hypersensitivity to fluticasone, salmeterol, or any excipients in the formulation. It is not recommended for patients with a history of life‑threatening asthma attacks who rely on short‑acting β2‑agonists alone, as LABA monotherapy can increase the risk of severe asthma events. Caution is also advised in individuals with cardiovascular disorders, hyperglycaemia, or active infections such as tuberculosis.

Risks, Side Effects, and Interactions

Common

• Oropharyngeal candidiasis (thrush) – mitigated by rinsing mouth after use.
• Hoarse voice or dysphonia.
• Cough or throat irritation immediately after inhalation.
• Mild headache.

Rare

• Systemic glucocorticoid effects (e.g., adrenal suppression, reduced bone mineral density) – generally observed with high cumulative doses.
• Pneumonia in patients with COPD.
• Dysglycaemia or worsening of diabetes control.

Serious

• Paradoxical bronchospasm – immediate worsening of wheeze or shortness of breath after inhalation; requires prompt medical assessment.
• Severe allergic reaction (anaphylaxis) – rare but life‑threatening; signs include angioedema, urticaria, or hypotension.
• Cardiovascular events (tachycardia, arrhythmia, hypertension) related to β2‑agonist activity, particularly in patients with pre‑existing heart disease.

Drug–Drug Interactions

• CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) can increase systemic exposure to fluticasone, raising the risk of corticosteroid‑related side effects.
• Non‑selective β‑blockers (e.g., propranolol) may blunt the bronchodilator effect of salmeterol.
• Diuretics or anti‑hyperglycaemic agents – monitor blood pressure and glucose, as LABA can cause mild hyperglycaemia.
• Other inhaled corticosteroids – concurrent use may lead to excessive glucocorticoid exposure; avoid unless directed by a specialist.

Practical Use: Dosing, Missed Dose, Overdose

• Standard adult dosing – One inhalation (containing 100 µg fluticasone propionate + 50 µg salmeterol) twice daily (morning and evening) is the most common regimen. Some patients may require a higher strength (e.g., 250 µg/50 µg) depending on disease severity and physician assessment.
• Administration technique – Shake the inhaler vigorously for 5 seconds, exhale fully, place the mouthpiece between lips, and press the canister while inhaling slowly and deeply. Hold breath for 10 seconds before exhaling. Repeat for the second daily dose.
• Missed dose – If a scheduled dose is forgotten, take it as soon as remembered unless the next regular dose is due within 2 hours; in that case, skip the missed dose and resume the normal schedule. Do not double‑dose.
• Overdose – Excessive exposure to inhaled corticosteroid may manifest as oral thrush, easy bruising, or hyperglycaemia; excess LABA may cause tremor, tachycardia, or palpitations. Seek medical advice promptly if symptoms develop.
• Precautions – Avoid using the inhaler with a spacer unless specifically instructed; inhaled corticosteroids may lose potency in certain plastic components. Alcohol does not affect inhaler function but may increase the perception of side effects such as tremor. Patients with liver impairment should be monitored, as both components undergo hepatic metabolism.

Buying Seroflo Inhaler from Our Online Pharmacy

Seroflo Inhaler can be purchased directly from our online pharmacy in Hong Kong. We specialise in providing vetted, cost‑effective generic alternatives that meet the same quality standards as brand‑name products such as Advair® or Wixela™.

• Affordable pricing – Our supply chain operates close to manufacturer cost, allowing us to offer prices that are substantially lower than retail pharmacy rates.
• Verified quality – All batches are sourced from GMP‑certified overseas manufacturers and undergo third‑party quality testing before dispatch.
• Guaranteed delivery – Discreet packaging ensures privacy; standard express shipping delivers within 7 days, while regular airmail typically arrives in 2–3 weeks.
• Online‑only access – For patients who encounter difficulty obtaining the inhaler through conventional pharmacy channels or insurance formularies, our pharmacy broker service connects you with licensed overseas suppliers while respecting confidentiality.

Our platform is designed for individuals seeking reliable, affordable access to essential respiratory medications without compromising safety.

FAQ

• What is the recommended storage temperature for Seroflo Inhaler?
  The inhaler should be stored at controlled room temperature, typically between 15 °C and 30 °C (59 °F–86 °F). Avoid extreme heat, freezing, or direct sunlight, as these conditions can affect propellant pressure and drug stability.

• Can Seroflo Inhaler be used during air travel?
  Yes. The inhaler is allowed in both carry‑on and checked luggage, but it is advisable to keep it in the cabin for easy access. Ensure the device is protected from high temperatures, such as those that may occur in a cargo hold.

• Does the inhaler contain any lactose or other allergens?
  Inactive ingredients include HFA‑134a propellant, ethanol, and oleic acid. The formulation does not contain lactose, egg protein, or common food allergens, making it suitable for most patients with dietary sensitivities.

• How does the inhaler differ from the original brand‑name product?
  The generic version contains the identical quantities of fluticasone propionate and salmeterol xinafoate and uses the same MDI technology. The primary differences lie in packaging and cost; therapeutic efficacy and safety profiles are equivalent when manufactured under GMP conditions.

• Is a spacer device compatible with Seroflo Inhaler?
  While the inhaler is designed for direct mouth‑to‑device use, a spacer can be employed if a patient has difficulty coordinating inhalation. However, some drug loss may occur, potentially requiring dose adjustments under medical supervision.

• What are the environmental considerations for disposing of the inhaler?
  The propellant (HFA‑134a) is a greenhouse gas, so the inhaler should not be discarded in regular household waste. Return empty canisters to a pharmacy collection program or follow local hazardous waste guidelines to minimize environmental impact.

• Can humidity affect the performance of the inhaler in Hong Kong’s climate?
  High humidity can increase the internal moisture content, potentially altering spray patterns. Storing the inhaler in a dry place, such as a cabinet away from bathroom vapour, helps maintain consistent dosing.

• Are there known differences in formulation between Asian and Western markets?
  Regulatory agencies may require minor variations in excipient sourcing or labeling, but the active ingredient concentrations and delivery mechanism remain consistent worldwide.

• How long does an opened inhaler remain effective?
  After the first actuation, the inhaler is typically usable for 30 days if stored correctly, provided the dose counter has not been exhausted. The propellant pressure gradually declines, and dosing accuracy may diminish beyond this period.

• What clinical trials supported the approval of the fluticasone‑salmeterol combination?
  Large, double‑blind, placebo‑controlled Phase III trials (e.g., the FACET and INSPIRE studies) demonstrated significant reductions in asthma exacerbations, improved lung function, and better symptom control compared with inhaled corticosteroid monotherapy. These data underpin the guideline recommendations for combination therapy.

• Does the inhaler interfere with drug testing for athletes?
  Fluticasone and salmeterol are not listed as prohibited substances by the World Anti‑Doping Agency (WADA). However, athletes should disclose therapeutic inhaler use to relevant sporting authorities to avoid misunderstandings.

• Can patients with mild liver impairment use Seroflo Inhaler safely?
  Both components are metabolised hepatically, but systemic exposure from inhaled administration is low. Mild liver dysfunction usually does not require dose modification, but regular monitoring is prudent.

Glossary

Fluticasone propionate

A synthetic glucocorticoid delivered by inhalation that suppresses airway inflammation by inhibiting cytokine production.

Salmeterol xinafoate

A long‑acting β2‑adrenergic agonist that relaxes bronchial smooth muscle, providing bronchodilation for up to 12 hours.

MDI (Metered‑Dose Inhaler)

A handheld device that releases a pre‑measured spray of medication, using a propellant to deliver the drug deep into the lungs.

Adverse event classification

A system that groups side effects as common (≥ 1 % incidence), rare (.01 %–1 %), or serious (life‑threatening or requiring hospitalization).

⚠️ Disclaimer

The information provided about Seroflo Inhaler is for general knowledge only. It does not replace professional medical consultation. All treatment decisions should be made under the supervision of a qualified healthcare provider. We assume all readers are responsible adults capable of making informed decisions about their health. Our online pharmacy offers access to Seroflo Inhaler for individuals who may have limited availability through traditional pharmacies, prescription‑based insurance schemes, or who are seeking affordable generic alternatives. Always consult your doctor before starting, changing, or discontinuing any medication.